^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | BLU-222 (CDK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.
Published date:
05/25/2023
Excerpt:
VELA (NCT05252416) is an international, open-label, phase 1/2 study evaluating the safety, PK, pharmacodynamics, and efficacy of BLU-222….One partial response was seen in a pt with HR+/HER2− metastatic breast cancer previously treated with 5 lines of therapy, including palbociclib, abemaciclib, and capecitabine.
DOI:
10.1200/JCO.2023.41.16_suppl.3095
Trial ID:
